Targeting the RAF/MEK/ERK, PI3K/AKT and P53 Pathways in Hematopoietic Drug Resistance

Overview

Journal Adv Enzyme Regul

Specialty Biochemistry

Date 2007 Mar 27

PMID 17382374

Citations 38

Authors

James A McCubrey

Linda S Steelman

Richard A Franklin

Steven L Abrams

William H Chappell

Ellis W T Wong

Brian D Lehmann

David M Terrian

Jorg Basecke

Franca Stivala

Massimo Libra

Camilla Evangelisti

Alberto M Martelli

Affiliations

Soon will be listed here.

Citing Articles

Inhibition of SGK1 potentiates the anticancer activity of PI3K inhibitor in NSCLC cells through modulation of mTORC1, p‑ERK and β‑catenin signaling.

Kale R, Samant C, Bokare A, Verma M, Nandakumar K, Bhonde M Biomed Rep. 2023; 19(6):94.

PMID: 37901878 PMC: 10603377. DOI: 10.3892/br.2023.1676.

Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents.

Rushing B Int J Mol Sci. 2023; 24(17).

PMID: 37686047 PMC: 10487847. DOI: 10.3390/ijms241713242.

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.

Li Q, Li Z, Luo T, Shi H Mol Biomed. 2022; 3(1):47.

PMID: 36539659 PMC: 9768098. DOI: 10.1186/s43556-022-00110-2.

Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells.

Tian S, Su R, Wu K, Zhou X, Vadgama J, Wu Y J Pers Med. 2022; 12(8).

PMID: 36013267 PMC: 9410505. DOI: 10.3390/jpm12081318.

Anticancer Properties of N,N-dibenzylasparagine as an Asparagine (Asp) analog, Using Colon Cancer Caco-2 Cell Line.

Mohamed E, Bassiouny K, Alshambky A, Khalil H Asian Pac J Cancer Prev. 2022; 23(7):2531-2540.

PMID: 35901362 PMC: 9727330. DOI: 10.31557/APJCP.2022.23.7.2531.

References

Thomas R, Tymms M, McKinlay L, Shannon M, Seth A, Kola I . ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Oncogene. 1997; 14(23):2845-55. DOI: 10.1038/sj.onc.1201125. View

Parry T . The non-random distribution of point mutations in leukaemia and myelodysplasia--a possible pointer to their aetiology. Leuk Res. 1997; 21(6):559-74. DOI: 10.1016/s0145-2126(97)83221-3. View

Songyang Z, Baltimore D, Cantley L, Kaplan D, Franke T . Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci U S A. 1997; 94(21):11345-50. PMC: 23462. DOI: 10.1073/pnas.94.21.11345. View

Datta S, Dudek H, Tao X, Masters S, Fu H, Gotoh Y . Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91(2):231-41. DOI: 10.1016/s0092-8674(00)80405-5. View

del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G . Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997; 278(5338):687-9. DOI: 10.1126/science.278.5338.687. View

Jimenez L, Zanella C, Fung H, Janssen Y, Vacek P, Charland C . Role of extracellular signal-regulated protein kinases in apoptosis by asbestos and H2O2. Am J Physiol. 1997; 273(5):L1029-35. DOI: 10.1152/ajplung.1997.273.5.L1029. View

Vogt P, Bader A, Kang S . Phosphoinositide 3-kinase: from viral oncoprotein to drug target. Virology. 2005; 344(1):131-8. DOI: 10.1016/j.virol.2005.09.027. View

Qi X, Wildey G, Howe P . Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem. 2005; 281(2):813-23. DOI: 10.1074/jbc.M505546200. View

Hiramatsu A, Miwa H, Shikami M, Ikai T, Tajima E, Yamamoto H . Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma. 2006; 47(1):89-95. DOI: 10.1080/10428190500270386. View

10.

Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M . KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 2005; 107(5):1806-9. DOI: 10.1182/blood-2005-08-3408. View

11.

Tallman M . New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol. 2006; 19(2):311-20. DOI: 10.1016/j.beha.2005.11.006. View

12.

Zebisch A, Staber P, Delavar A, Bodner C, Hiden K, Fischereder K . Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res. 2006; 66(7):3401-8. DOI: 10.1158/0008-5472.CAN-05-0115. View

13.

Conde de la Rosa L, Schoemaker M, Vrenken T, Buist-Homan M, Havinga R, Jansen P . Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases. J Hepatol. 2005; 44(5):918-29. DOI: 10.1016/j.jhep.2005.07.034. View

14.

Lee J, Kim S, Hwa Kwon C, Kim Y . EGFR-dependent ERK activation triggers hydrogen peroxide-induced apoptosis in OK renal epithelial cells. Arch Toxicol. 2005; 80(6):337-46. DOI: 10.1007/s00204-005-0052-2. View

15.

Martelli A, Nyakern M, Tabellini G, Bortul R, Tazzari P, Evangelisti C . Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 2006; 20(6):911-28. DOI: 10.1038/sj.leu.2404245. View

16.

Dahia P, Aguiar R, Alberta J, Kum J, Caron S, Sill H . PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet. 1999; 8(2):185-93. DOI: 10.1093/hmg/8.2.185. View

17.

Flotho C, Valcamonica S, Schmahl G, Corral L, Ritterbach J, Hasle H . RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999; 13(1):32-7. DOI: 10.1038/sj.leu.2401240. View

18.

Gewirtz D . A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999; 57(7):727-41. DOI: 10.1016/s0006-2952(98)00307-4. View

19.

Romanelli A, Martin K, Toker A, Blenis J . p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex. Mol Cell Biol. 1999; 19(4):2921-8. PMC: 84086. DOI: 10.1128/MCB.19.4.2921. View

20.

Butler M, Wang S, Chaganti R, Parsons R, Dalla-Favera R . Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes Cancer. 1999; 24(4):322-7. View